GVS advice onosilodrostat (Isturisa®) for the treatment of endogenous Cushing syndrome

The National Health Care Institute has completed its assessment whether osilodrostat (Isturisa®) can be included in the Medicine Reimbursement System (GVS). Osilodrostat (Isturisa®) is registered for the treatment of endogenous Cushing syndrome in adults. The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V.

Indication for which reimbursement is requested

Isturisa® is available as a film-coated tablet with 1, 5 or 10 mg osilodrostat (as osilodrostat phosphate) and is registered for the treatment of endogenous Cushing syndrome in adults. 

National Health Care Institute's advice

The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.